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Introduction: Surgical resection remains the only potentially curative treatment for colorectal liver
metastases (CLM). However, involvement of both the hepatic lobes or extrahepatic disease (EHD) can be
a contra-indication for resection. The aim of the present study was to examine the addition of combined
positron emission and computed tomography (PET/CT) to CLM staging to assess the effects upon
staging and management.
Methods: All CLM patients referred to a single centre between January 2005 and January 2009 were
prospectively included. All underwent routine staging (clinical examination and computed tomography),
followed by a whole body 18fluoro-deoxy-glucose (18FDG)-PET/CT scan and Fong clinical risk score
calculation.
Results: Sixty-four patients were included [63% male with a median age of 63 years (age range 32–79
years)]. The addition of PET/CT led to disease upstaging in 20 patients (31%) and downstaging in two
patients (3%). EHD was found in 24% of low-risk patients (Fong score 0–2) as compared with 44% of
high-risk patients (Fong score 3–5) (P = 0.133). There was a trend towards a greater influence upon
management in patients with a low score (44% vs. 17%; P = 0.080).
Conclusion: The addition of PET/CT led to management changes in over one-third of patients but there
was no correlation between alterations in staging or management and the Fong clinical risk score;
suggesting that PET/CT should be utilized, where available, in the pre-operative staging of CLM patients.
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Introduction
Over 37 000 diagnoses of colorectal cancer (CRC) are made per
annum in the UK, up to 9000 of which will have liver metastases
at the time of diagnosis,1 and approximately 50% of which will
develop spread to the liver during the course of disease; where
they will be responsible for up to two-thirds of all CRC
deaths.2 The management of colorectal liver metastases (CLM)
continues to evolve but surgical resection remains the only
potentially curative treatment and the current approach
is that resection is indicated if the metastases are resectable
and sufficient residual liver will remain post-operatively
to prevent hepatic failure.3–5 Current contra-indications
to resection include a non-treatable primary tumour or wide-
spread nodal, locoregional or metastatic (pulmonary, bony and
peritoneal) disease; although, certain patients with resectable or
ablatable extrahepatic disease (EHD) remain suitable for
resection.6
Overall, survival rates after resection for CLM are 26–60% at 5
years,4,7–9 17–26% at 10 years4,10–12 and 26% for those with EHD;13
whereas, post-operative mortality is 1.5–2.8%.4,11 Recurrence
within the liver is the commonest cause of treatment failure;
however, second or third resections can be performed for recur-
rent metastases with similar 5-year survival rates to first resection
(34% and 32% respectively) and an acceptable post-operative
morbidity rate.14
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However, even within selected subgroups of patients with resec-
table disease, there is wide variability in recurrence rates and
survival after resection. Independent predictors of poor survival
after resection include multiple hepatic metastases, a poorly-
differentiated or node positive primary tumour, EHD, tumour
diameter 5 cm, significantly raised carcinoembryonic antigen
levels (CEA), positive resection margins and a short disease-free
interval from development of primary to development of
metastases (less than 12 months).4,11 Reliable, prognostically accu-
rate and widely-applicable molecular markers for CLM are yet to
be identified, and such disease-related clinical variables are often
utilized to risk-stratify patients.11,15 In 1999 Fong et al.11 assessed
1001 consecutive CLM patients to become the first group to syn-
thesize a pre-operative clinical risk score. The Fong score incor-
porated node status, number and size of tumour, disease-free
interval and CEA level (see Table 1) in a fashion that was found to
be highly predictive of outcome: low scores (two or less out of five)
were associated with a favourable outcome, whereas high scores
(five out of five) were not associated with a long-term prognosis
(see Fig. 1).
The accuracy of pre-operative staging is pivotal for the correct
implementation of such scoring systems and a number of
modalities are routinely utilized to image the liver, including
ultrasound (US), contrast-enhanced multi-detector computed
tomography (CEMDCT) and magnetic resonance imaging
(MRI).16 However, many of these techniques remain limited as
the tumour burden is often underestimated, particularly in
extra-hepatic disease.17 Combined positron emission and com-
puterized tomography (PET/CT), utilizing 18fluro-deoxy glucose
(18FDG) produces a fusion image combining conventional cross-
sectional, anatomical imaging of CT with the biological, func-
tional imaging of PET.18 It can be utilized to identify and stage
primary colorectal tumours19 as well as metastases18 and has also
been used to great effect in the staging of anal squamous cell,20
pancreatic21 and lung22 cancers.
The present study examined the pre-treatment staging of
CLM by PET/CT to investigate whether it could alter the
staging of local or distant disease and management. Further, we
aimed to compare the Fong clinical risk score with PET/CT yield




All patients referred to a single centre for potential resection of
CLM, between January 2005 and January 2009, were prospectively
included in the present study. All had previously undergone R0
(complete histological clearance) resection of a primary colorectal
tumour and all patients underwent routine staging, consisting of
clinical examination and a CEMDCT scan of the thorax, abdomen
and pelvis. All patients also underwent a whole body 18FDG-
PET/CT scan performed within 2 weeks of CEMDCT at the same
institution, as part of their standard pathway of care (therefore, no
ethical approval was sought for the study).
A clinical risk score was calculated for each patient (range 0–5),
as per the Fong criteria (see Table 1 and Fig. 1):11 a clearly-defined
and widely-applicable score of clinical criteria for the selection of
patients likely to benefit from resection of CLM. The patients were
divided into low risk (Fong score 0–2; five-year survival 40% or
higher) and high risk for recurrence (Fong score 3–5; five-year
survival 20% or less), as per the original scoring system.
All patients were reviewed in a specialist hepatobiliary, multi-
disciplinary team (MDT) meeting, consisting of hepatobiliary
surgeons, oncologists, pathologists and radiologists with an
interest in radiofrequency ablation (RFA). The MDT was ini-
tially blinded to the results of the PET/CT scans, which were
reported by a dual-trained nuclear medicine and radiology phy-
sician with over 5 years experience of reviewing PET/CTs, and
who in turn was blinded to the results of the standard imaging.
A PET/CT lesion was identified as being ‘positive’ according to
the considered opinion of the reporting physician. An initial
management decision was made based upon standard imaging
and the results of the PET/CT scan were subsequently revealed
and a new management plan created. The results of the PET/CT
scan results were then correlated with the Fong clinical risk
score.
PET/CT protocol
One hour before the examination, 370MBq of 18FDG was injected
intravenously. Utilizing a dedicated combined GE Discovery LS
PET/CT unit (GE Advance PET scanner and the GE Light-speed
CT; General Electric Company, Fairfield, CT, USA), whole-body
examinations were performed with the patient supine and arms
held above the head. CT was performed using four 3.75-mm
detectors, a pitch of 1.5 and a 5-mm collimation. The CT exposure
factors for all examinations were 140 kVp and 80 mA in 0.8 s.
Maintaining the patient position, a whole body PET emission scan
was performed, covering an area identical to that of a CT (5–6 bed
positions). All acquisitions were carried out in a 2-dimensonal
(2D) mode and consisted of emission scans of 5 min per bed
position. PET images were reconstructed using CT for attenuation
correction by employing CT maps. Transaxial emission images of
4.3 ¥ 4.3 ¥ 4.25 mm3 (in plane matrix size 128 ¥ 128) were recon-
structed using ordered subsets expectationmaximization (OSEM)
Table 1 Fong score criteria for determination of prognosis in patients
with colorectal liver metasatasis (CLM). The patient scores one point
for each criteria they meet (adapted from Fong et al.11)
Lymph node + ve primary tumour
Disease-free interval < 12 months
>1 Tumour
Tumour size > 5 cm
CEA level > 200 ng/ml
CEA, carcinoembryonic antigen.
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with two iterations and 28 subsets. The axial field of view was
148.75 mm, resulting in 35 slices per bed position.
Statistical analysis
Statistical analysis was performed using an SPSS (Statistical
Package for the Social Sciences Inc., Chicago, IL, USA) software




Sixty-four consecutive patients with colorectal liver metastases, all
of which had undergone PET/CT as part of their standard
pathway of care, were included in the present study. Forty
(63%) were male and the median age was 63 years (age range
32–79 years). None of the patients underwent neoadjuvant
chemotherapy.
Effect of PET/CT inclusion in the staging protocol
Inclusion of PET/CT in the staging protocol resulted in additional
information in 28 patients (43%) and a change of management in
22 patients (34%).
Management changes occurred secondary to disease upstaging
in 20 patients (31%) and downstaging in two patients (3%).
Disease upstaging occurred as a result of the discovery of peri-
toneal disease in six patients, multiple lung metastases in six
patients, retroperitoneal lymph nodes in four patients, mediasti-
nal lymph nodes in two patients, porta hepatis nodes in one
patient and a previously undiagnosed thyroid cancer with bone
metastases in a further patient. Thirteen out of 20 lesions identi-
fied were new, whereas seven had been labelled as indeterminate
or suspicious on CT alone (two patients with peritoneal disease,
two with retroperitoneal lymphadenopathy, two with lung lesions
and one with porta hepatis nodes). The patient with thyroid
cancer underwent surgical resection to remove the thyroid lesion;
however, primary treatment for CLM in upstaged patients was
changed from surgical resection to chemotherapy.
The two patients downstaged were reported to have lung
metastases on CEMDCT; however, the lung lesions were not FDG
avid and were therefore thought to represent chronic airways
disease after PET/CT. Both patients were subsequently deemed fit
for surgery after pre-operative optimization.
Comparison with Fong clinical risk scores
Of the 64 patients, 46 (72%) had Fong scores of 0–2 (low-risk
of recurrence) and 18 (28%) had scores of 3–5 (high-risk of
recurrence).
Eleven out of 46 low-risk patients were found to have EHD on
PET/CT, as compared with eight out of 18 high-risk patients
(Fisher’s exact test: P = 0.133). However, although not significant,
there was a trend towards a greater influence upon management
in those patients with a low clinical risk score (0–2): 20 out of 46
low-risk patients underwent management alterations after PET/
CT, as compared with only three out of 18 high-risk patients with
a clinical risk score of 3–5 (Fisher’s exact test: P = 0.080).
Discussion
The results of the present study demonstrate that the use of
PET/CT in CLM patients is associated with alterations in patient
management in approximately one-third of patients (34%) (par-
Figure 1 The Fong clinical risk score predicts survival up to 5 years in patients with colorectal liver metastases, as calculated from 1001
consecutive patients by Fong et al. (1999) (adapted from Fong et al.11)
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ticularly owing to disease upstaging) but that there was no corre-
lation between alterations in staging or management and the Fong
clinical risk score.
Biological and multi-modality imaging, in the form of PET and
PET/CT, are now being increasingly utilized within the UK.
PET/CT works via the preferential accumulation and metabolic
trapping of a radiolabelled glucose analogue, 2-[18 F] fluoro-2-
deoxy-D-glucose (FDG), within malignant cells.18,23 The func-
tional nature of the image rendered, which relies upon ametabolic
evaluation of glucose uptake, rather than size or morphological
criteria alone, may allow the evaluation of smaller tumours at an
earlier point in their natural history, and a true integrated PET/CT
system also allows good anatomical definition by circumventing
the lack of an anatomical reference frame found with isolated PET.
A meta-analysis performed by Kinkel et al. in 200224 found that
FDG-PET was the most sensitive method for the detection of liver
metastases from multiple gastrointestinal origins, with a mean
weighted sensitivity of 90–92%, a result confirmed by Arulam-
palam et al.25,26 in two separate studies: one investigating 42
patients with suspected recurrent CRC to discover that FDG-PET
was more accurate than CT (sensitivity 100% vs. 45%; specificity
100% for both) and one in 28 patients with confirmed CLM to
demonstrate a sensitivity and specificity of FDG-PET of 100%
and 91%, respectively, as compared with 47% and 91% for CT.
More recent meta-analyses confirm these initial results. A meta-
analysis of 25 articles published between 2000 and 2008 demon-
strated that sensitivity and specificity, on a per-patient basis, for
ultrasound, CT,MRI and FDG-PET in the detection of CLM were
63.0% and 97.6%, 74.8% and 95.6%, 81.1% and 97.2, and 93.8%
and 98.7%, respectively; whereas, on a per lesion basis sensitivity
was 86.3%, 82.6%, 86.3% and 86.0%, respectively.27 Further,
Wiering et al.28 found that FDG-PET had a pooled sensitivity and
specificity of 88.0% and 96.1%, respectively, for hepatic disease,
and 91.5% and 95.4% for EHD, results that were significantly
higher than CT (82.7% and 84.1% for hepatic; 60.9% and 91.1%
for EHD).
Integrated PET/CT has also been shown to be superior to PET
alone in the assessment of primary colorectal tumours,19 as well as
recurrent and metastatic disease;29 and results to date suggest that
it may also be superior to many imaging modalities in the assess-
ment of liver metastases. Cohade et al.19 performed a retrospective
review of 45 CRC patients to show that more definitely normal
and definitely abnormal lesions were identified with PET/CT than
with PET alone. The accuracy of staging and restaging also
improved from 78% to 89%.
Grassetto et al.30 similarly assessed a mixed cohort of patients
with solitary liver metastases (18 CRC, 15 non-small cell lung
cancer, six breast carcinoma and four ovarian cancer) to dem-
onstrate that PET/CT restaged disease and changed therapy in
28% of patients. Chua et al.31 compared CEMDCT and 18FDG-
PET/CT in 131 patients with liver metastases (75 CRC and 56
other tumours) to show that PET/CT yielded a sensitivity and
specificity of 94% and 75%, compared with 91% and 25%,
respectively, for CEMDCT. Improvements in staging accuracy
were associated with alterations in patient management in 25%
of patients.
Discovery of such EHD has been shown to be crucial in pre-
venting unnecessary intervention. Wiering et al.32 prospectively
compared 100 CLM patients staged via conventional techniques,
with 103 patients staged with an additional FDG-PET to demon-
strate a reduction in the number of negative laparotomies bymore
accurate prediction of EHD. Similarly, Ruers et al.33 randomized
150 CLM patients selected for surgical resection by CT imaging
alone (n = 75) or CT plus FDG-PET (n = 75) to demonstrate a
significantly decreased number of futile laparotomies (45% vs.
28%; P = 0.042).
In those deemed unsuitable for operative intervention, sys-
temic chemotherapy regimens can be used in a subset (12.5%34)
of patients to reduce tumour load and potentially allow certain
patients to subsequently undergo resection.34–36 The use of FDG-
PET in such circumstances may have additive effects in the
monitoring of tumour metabolism and response: Vriens et al.37
examined the effects upon CLM functional tumour metabolism
assessed by FDG-PET, prior to and following three chemo-
therapy cycles in 23 CLM patients to find that glucose metabolic
rates decreased significantly during treatment (P < 0.001).
Currently, PET/CT is not readily available within the UK: the
technology remains relatively novel, as well as being expensive and
constantly evolving, and there is a shortage of PET/CT scanners,
as well as trained and experienced staff available to operate them.38
Further, new technologies are being constantly discovered and
investigated, with some groups even looking at computer-
automated discovery of liver lesions.39,40
After the development of the Fong score, five large predictive
models have been published with considerable overlap of key
independent predictors of long-term outcome. Utilization of such
prognostic scores yields stark differences between patients in
good- and poor-risk categories, with 5-year survival rates ranging
from 60% to <15%, respectively.4,11,15 However, there remains a
need for a universally-adopted predictive model,41 which may be
used to pre-operatively improve selection for surgery, and post-
operatively risk-stratify patients who may benefit from intensive
surveillance and adjuvant therapies.
Conclusion
This article presents 64 prospectively-studied CLM patients to
demonstrate that the addition of PET/CT to staging provided
additional information, in particular the discovery of EHD that
led to management changes in 34% of patients. These data suggest
that PET/CT should be used where available in the pre-operative
staging of these patients.
The influence on management provided by the addition of
PET/CT was undoubtedly greater in the lower risk group (44%)
than the high risk group (14%) but this failed to reach statistical
significance. Based on this series, the Fong clinical risk score
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should not be used to rationalize the use of PET/CT in those
patients being investigated for potential resection of CLM.
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